Idya investor relations
Web6 apr. 2024 · IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives $28.00 Consensus Price Target from Analysts americanbankingnews.com - April 4 at 1:00 AM: IDEAYA Biosciences to Participate in Upcoming April 2024 Investor Relations Event finance.yahoo.com - April 3 at 7:58 AM: IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing … Web8 dec. 2024 · - On track for topline ARTEMIS-UC Phase 2 and full APOLLO-CD Phase 2a results concurrently in 4Q 2024 - - Initiation of Phase 1 trial of second precision program …
Idya investor relations
Did you know?
Web16 mrt. 2024 · About Us Our Commitments Our Networks News & Media Investor Center Careers. Contact and calendar. Financial calendar. Date Event Export to my calendar; 03.16.2024: FY 2024 Results: Add. Investor contact. Head of Investor Relations: Nicolas Didio. E-mail: [email protected]. Our corporate foundation. Information. Documentation. Quality … Web10 apr. 2024 · Investor Resources NASDAQ: DICE Common Stock $27.18 +0.35 (+1.30%) Apr 10, 2024 4:00 PM EDT Data Provided by Refinitiv. Minimum 15 minutes delayed. …
Web7 mrt. 2024 · South San Francisco, CA, March 7, 2024. – IDEAYA Biosciences, Inc. (Nasdaq:IDYA), a synthetic lethality focused precision medicine oncology company … WebIDEAYA Biosciences, Inc. is a synthetic lethality-focused precision medicine oncology company. The Company is engaged in the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its lead product candidates are darovasertib (IDE196), IDE397 and IDE161.
Web4 jan. 2024 · IDEAYA to Participate in Upcoming January 2024 Investor Relations Events and Scientific Conferences. News provided by. IDEAYA Biosciences, Inc. Jan 04, 2024, … WebVeru is a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral and ARDS-related diseases and for the management of breast and prostate cancers.
Web1 mrt. 2024 · SOUTH SAN FRANCISCO, Calif., March 1, 2024-- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company …
Web3 apr. 2024 · April 3, 2024 - 6:00 am. SOUTH SAN FRANCISCO, Calif., April 3, 2024-- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation in upcoming investor relations event(s). glendale healthcare associates llcWebInvestor Relations IDEAYA Biosciences - SEC Filings Financial Information Snapshot SEC Filings Analyst Coverage Key Ratios Select the filing type and date range you wish to view from the drop-down menus below. NASDAQIDYA glendale healthcareglendale health centerWeb1 mrt. 2024 · March 1, 2024 - 6:00 am. SOUTH SAN FRANCISCO, Calif., March 1, 2024-- IDEAYA Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced its participation at the following upcoming investor relations events. body mass index of 30.5WebThe Board of Directors recommends that you vote FOR the election of the director nominees named in Proposal No. 1 of the Proxy Statement; and FOR the ratification of the appointment of PricewaterhouseCoopers LLP, as the independent registered public accounting firm, as described in Proposal No. 2 of the Proxy Statement.. YOUR VOTE IS … glendale health center naugatuckWeb6 sep. 2024 · filecache.investorroom.com glendale healthcare center addressWeb11 rijen · Investor Relations. About KalVista. Senior Management; Board of Directors; … body mass index of 32